Structure Based Prediction of Asparagine Deamidation Propensity in Monoclonal Antibodies

Qingrong Yan, Maggie Huang, Michael J. Lewis, and Ping Hu

ABSTRACT
Identification of asparagine (Asn) sites that are prone to deamidation is critical for the development of therapeutic monoclonal antibodies (mAbs). Despite a common chemical degradation pathway, the rates of Asn deamidation can vary dramatically among different sites, and prediction of the sensitive deamidation sites is still challenging. In this study, characterization of Asn deamidation for five IgG1 and five IgG4 mAbs under both normal and stressed conditions revealed dramatic differences in the Asn deamidation rates. A comprehensive analysis of the deamidation sites indicated that the deamidation rate differences could be explained by differences in the local structure conformation, structure flexibility and solvent accessibility. A decision tree was developed to predict the deamidation propensity for all Asn sites in IgG mAbs based on the analysis of these three structural parameters. This decision tree will allow potential Asn deamidation hot spots to be identified early in development.

Introduction
Deamidation of neutrally charged asparagine (Asn) residues to negatively charged aspartate (Asp) or isoaspartate (isoAsp) residues is a common degradation pathway that occurs during the manufacturing and storage of monoclonal antibodies (mAbs). Deamidation of several Asn residues in the complementary-determining regions (CDRs) of IgG mAbs have been reported to affect antigen binding. Recent studies have also shown that changes in the charge distribution on the protein surface could alter mAb pharmacokinetics (PK) by affecting FcRn-IgG dissociation. Thus, the potential risk of deamidation at each site needs to be evaluated to ensure product stability.

The molecular mechanism of Asn deamidation has been well studied (Figure 1). In this degradation pathway, the side-chain carbonyl group of Asn is attacked by the deprotonated backbone NH group of the adjacent C-terminal residue to generate a cyclic succinimide intermediate. The cyclic succinimide is formed from an unstable tetrahedral intermediate and can be detected under low pH conditions. At neutral and basic pH, the succinimide intermediate is rapidly hydrolyzed at either of the carbonyl centers to form Asp or isoAsp. The ratio of Asp to isoAsp varies depending on the reaction buffer and local structural environment.

A reliable model is needed to predict the propensity of Asn deamidation and design more robust protein therapeutics and develop a suitable control strategy to ensure product quality. Currently, potential deamidation “hot spots” are still commonly identified based on primary sequence motifs such as NG and NS that were derived from a pentapeptide model system. However, the same primary sequence motifs can have different rates of Asn deamidation depending on the higher order structure and storage conditions of the protein. Some of these predicted “hot spots” have low or non-detectable levels of deamidation in reality because of geometric constraints imposed by secondary or tertiary structural elements in a fully folded antibody.

The difficulty in predicting deamidation propensity based on amino acid sequence motifs alone suggests that a more detailed structural analysis is needed. After evaluating many structural parameters of the peptide bond, the distance between the nucleophilic NH group of the adjacent C-terminal residue and the Cy center of the Asn side chain (Cy-N distance) was considered a key factor influencing the deamidation rate (Figure 1). It was proposed that a Cy-N distance of 1.89 Å was favorable for forming the succinimide intermediate, and this distance could be obtained if the dihedral psi (ψ) angle for rotation around the α-C bond was −120° and the chi1 (X1) angle for rotation around the ω-Cβ bond was 120°. However, this ideal peptide geometry is rarely observed in known protein structures because of constraints imposed by secondary and tertiary structural elements. For example, the hydrogen bond network between the β-strands would constrain the flexibility of the Asn residue and limit its ability to adopt the above-mentioned conformation. In addition, if a backbone NH group is involved in a hydrogen bond, its ability to induce a nucleophilic attack on the Asn side chain is significantly reduced. Based on Clarke’s theoretical model of Asn deamidation, Xie et al have suggested that the minimum distance for the formation of the Cy-N bond for β-turn and loop structures ranges between 3.1 and 3.3 Å. This distance is much longer than the typical C-N bond of 1.4–
1.5 Å, suggesting that the deamidation rates for Asn residues within a folded protein would be much slower than the rates observed in less structured peptides.

Although a number of new methods combining primary and tertiary structural information to predict Asn deamidation sites have been presented, a more systematic analysis of protein structure dynamics is needed to improve the reliability of these predictions. Here, IgG mAbs were chosen as protein models to study the correlations between Asn deamidation rates and protein structural features. Forced degradation studies using a combination of high pH and heat stress were performed to experimentally identify the sensitive Asn deamidation sites in mAbs. The deamidation levels were quantified by liquid chromatography (LC)/mass spectrometry (MS) peptide mapping analysis and exponential first-order kinetics models were used to calculate the deamidation rate constants for each Asn site. The structural features that were responsible for different deamidation rates were then determined and a decision tree was constructed that can be used to identify Asn deamidation “hot spots”.

Results

Deamidation of IgG1 mAbs under normal and stressed conditions

Five therapeutic IgG1 mAbs were included in the deamidation analysis. All mAbs were fully human IgG1 mAbs except mAb2, which was a murine/human chimeric mAb with a human IgG1 constant region sequence. All mAbs were stored at −70°C in an acidic formulation buffer (5.0 – 5.8) to minimize Asn deamidation. To induce deamidation, mAb samples were incubated at 37°C in the formulation buffer at pH 5.0 – 5.8 for up to 180 days and phosphate buffer at pH 8.5 for up to 30 days. The antibody samples incubated in phosphate buffer at pH 8.5 were dialyzed back to their original formulation buffer at pH 5.0 – 5.8 for up to 180 days and phosphate buffer at pH 8.5 for up to 30 days. The antibody samples incubated in phosphate buffer at pH 8.5 were dialyzed back to their original formulation buffer at pH 5.0 – 5.8 for up to 180 days and phosphate buffer at pH 8.5 for up to 30 days. The antibody samples incubated in phosphate buffer at pH 8.5 were dialyzed back to their original formulation buffer at pH 5.0 – 5.8 for up to 180 days and phosphate buffer at pH 8.5 for up to 30 days. The antibody samples incubated in phosphate buffer at pH 8.5 were dialyzed back to their original formulation buffer at pH 5.0 – 5.8 for up to 180 days and phosphate buffer at pH 8.5 for up to 30 days.

Peptide mapping with LC/MS/MS analysis was used to identify and quantify Asn deamidation in all samples. The deamidation reaction kinetics followed exponential first-order kinetics and rate constants were calculated as described in the Methods and Materials section.

As shown in Supplementary Table 1, only 6 of the 29 Asn residues in the fragment variable (Fv) region of unstressed mAbs had deamidation levels > 0.5% (heavy chain (HC) Asn57, light chain (LC) Asn93, HC Asn43, LC Asn28, LC Asn53 and HC Asn55). HC Asn43 was the most sensitive site, with >70% deamidation under normal, unstressed storage conditions. The levels of deamidation at the other 5 sites were <5%. Although the deamidation levels increased after heat stress in acidic formulation buffer, only LC Asn93, HC Asn43 and HC Asn55 had deamidation increase > 5% and all rate constants were less than 1.0 x 10⁻³ day⁻¹ (Figure 2A, Supplementary Table 2). In contrast, HC Asn57, LC Asn28, LC Asn53 and HC Asn55 deamidation increased >5% after heat stress in phosphate buffer at pH8.5, with rate constants ranging from 2.3 x 10⁻³ day⁻¹ to 29.4 x 10⁻³ day⁻¹ (Figure 2A, Supplementary Table 2).

In summary, HC Asn57, LC Asn93, HC Asn43, LC Asn28, LC Asn53 and HC Asn55 were identified as deamidation “hot spots” in the Fv region. These sites were all located in the complementarity-determining regions (CDRs) of the mAbs, and their deamidation rates were higher at pH 8.5 than pH 5–6, which were consistent with previous reports. These results imply that the conformation of Asn residues in the CDR loops were unique and more prone to deamidation than the Asn residues in other Fv regions.

As shown in Supplementary Table 3, only 5 of the 10 Asn residues (glycosylation site Asn297 was excluded in this analysis) in the conserved Fc region of unstressed mAbs had deamidation levels > 0.5%, HC Asn315, HC Asn325, HC Asn384/389, and HC Asn434. HC Asn315 and HC Asn384/389 were the most sensitive sites, with >5% deamidation under normal, unstressed storage conditions. These results were consistent with previous reports. It should be noted that HC Asn315 is not considered a deamidation hot spot even though up to 8% deamidation was detected in unstressed mAbs because HC Asn315 contains the sensitive NG sequence motif and much of the deamidation detected at this site occurred during peptide map analysis (unpublished observations). Similar method related artifacts were also reported previously.

Only HC Asn325 deamidation increased >5% after heat stress in acidic formulation buffer, with rate constants ranging from 2–3 x 10⁻³ day⁻¹ (Figure 2B, Supplementary Table 3). However, its deamidation rate constants were reduced to ~ 0.5 x 10⁻³ day⁻¹ at pH 8.5 (Figure 2B). The rate constant for HC Asn325 deamidation was further decreased at neutral pH (0.1 x 10⁻³ day⁻¹, data not shown). The observation that the deamidation rate for HC Asn325 residue was much greater under heat stress in acidic pH than basic or neutral pH was opposite that for other Asn sites, which typically have increased deamidation in higher pH solutions. On the other hand, only HC Asn384/389 deamidation increased >5% after heat stress in basic phosphate buffer, with rate constants ranging from 73 x 10⁻³ day⁻¹ to 144 x 10⁻³ day⁻¹ (Figure 2C, Supplementary Table 4).

| Table 1. Structural analysis of HC Asn325 from IgG1 and IgG4 Fc structural models in the PDB. |
|-----------------------------------------------|
| IgG | PDB ID | pH | Resolution (Å) | Cy-N distance (Å) | SASA⁺ (Å²) by MOE | Chain |
|-----|--------|----|----------------|------------------|-------------------|-------|
| IgG1 | 3AVE | 7.0 | 2.0 | 3.3 | 3.07 | A |
| 3V7M | 5.1 | 2.0 | 3.4 | 18.98 | A |
| 4BYH | 4.0 | 2.3 | 3.2 | 13.99 | B |
| 2DTS | 7.0 | 2.2 | 3.2 | 3.93 | A |
| 4DZ8 | 7.0 | 1.9 | 3.5 | 5.54 | A |
| 3D6G | 6.5 | 2.3 | 3.4 | 2.43 | A |
| 4W4O | 4.6 | 1.8 | 3.2 | 11.12 | A |
| 4W4N | 6.1 | 1.8 | 3.2 | 4.26 | B |
| 3SGJ | 6.0 | 2.2 | 3.3 | 6.90 | A |
| 4B7J | 5.5 | 2.3 | 3.3 | 6.89 | B |
| 1L6X | 6.0 | 1.65 | 3.0 | 6.20 | A |
| IgG4 | 4C55 | 6.5 | 2.4 | 4.7 | 24.2 | A |
| 4C54 | 6.5 | 1.9 | 4.7 | 22.9 | A |
| 5WSM | 5.5 | 1.9 | 4.6 | 25.5 | A |

a SASA = Solvent Accessible Surface Area.
b MOE = Molecular Operating Environment software package.
Table 2. Structural analysis of Asn deamidation in the Fc region.

| Group | Residue Number | Sequence Motif | Secondary Structure | Cy-N distance (Å) | SASA * | Deamidation Under Normal Storage Conditions d | Deamidation Under Stressed Conditions d |
|-------|----------------|----------------|---------------------|------------------|--------|---------------------------------------------|----------------------------------------|
| I     | HC Asn276      | KFNWY          | β-sheet             | 4.6              | 14.2   | Low                                        | Low                                    |
|       | HC Asn361      | TKNQV          | β-sheet             | 4.6              | 78.1   | Low                                        | Low                                    |
|       | HC Asn390      | ENNYK          | β-sheet             | 4.3              | 34.8   | Low                                        | Low                                    |
| II    | HC Asn286      | VHNAK          | loop                | 3.8              | 56.7   | Low                                        | Low                                    |
|       | HC Asn315      | WLNGK          | α-helix             | 4.9              | 64.5   | Low                                        | Low                                    |
|       | HC Asn421      | QGNVF          | loop                | 4.4              | 26.4   | Low                                        | Low                                    |
| III   | HC Asn434      | LHNHY          | β-turn              | 4.9              | 74.0   | Low                                        | Low                                    |
|       | HC Asn325      | VSNKA          | β-turn              | 3.2              | 6.7    | Low                                        | Moderate                               |
| IV    | HC Asn384      | ESNGQ          | β-turn              | 5.0/2.8 b        | 73.2/83.4 | Moderate                                  | High                                  |
|       | HC Asn389      | PENNY          | loop                | 4.3/3.3 c        | 70.0/73.5 | Moderate                                  | High                                  |

* SASA = Solvent Accessible Surface Area.

b N-Cy distances of two alternative conformations of Asn384.

c N-Cy distances of two alternative conformations of Asn389.

d Level of deamidation was summarized to three levels by values from LC/MS peptide mapping results. Low: between undetectable to 5%; Moderate: between 5% to 10%; High: over 10%.

Figure 1. Mechanism of Asparagine (Asn) Deamidation. Schematic representation of L-Asn deamidation, which can occur spontaneously by nucleophilic attack of the C-terminal adjacent peptide bond nitrogen atom on the side chain carbonyl group of L-Asn. This step leads to the formation of a tetrahedral intermediate, which quickly generates cyclic imide intermediate (succinimide). In the second step, succinimide undergoes hydrolytic attack at both carbonyl centers, leading to formation of Asp and isoAsp isoforms. The rate determining step for the deamidation process is the cyclization step leading to the succinimide intermediate, which is regulated by dihedral angles (Ψ and Φ) and Cy-N distance.

In summary, 6 Asn residues in the Fv region and 3 Asn residues in Fc region were sensitive to deamidation under normal storage or heat stress conditions. These results suggested that deamidation propensity cannot be determined from the sequence motif alone because only 4 of the 14 sites with an NG or NS sequence motif were sensitive to deamidation. In addition, LC Asn93 and LC Asn28 had NW and NI sequence motifs, which had very low deamidation rates in the pentapeptide model. Thus, a comprehensive correlation between the deamidation rates and three-dimensional structures was performed in order to better understand the structural impact on deamidation rates.

**Structural analysis of Asn384/389 deamidation**

HC Asn384 and Asn389 residues located in the PENNY peptide of the Fc region are well-known deamidation hot spots, especially under high pH stress conditions. As shown in Figure 2C, the deamidation rates increased significantly under heat stress at pH 8.5, with half-times ranging between 4 and 10 days for all three tested mAbs. Interestingly, the levels of deamidation plateaued after 10 days and never reached 100%. These results suggested that there may be two different rates for Asn384/389 deamidation, although more data points at the extended incubation time are needed to define a biphasic model. To compare deamidation rates with other sites, the HC Asn384/389 deamidation rate from the fast phase was determined by setting the maximal deamidation level at 60% in the exponential kinetic model. The Asn384/389 deamidation rate ranged from 70 ~ 144 x 10^-3 day^-1, which was the highest among all Asn sites. The R square values for all three mAbs were >0.99.

To understand the molecular basis for the biphasic nature of HC Asn384/389 deamidation, peptide geometries for HC Asn384 and HC Asn389 from over 20 human IgG1 Fc structures available in the RCSB Protein Database Bank (PDB) were analyzed, which revealed that both residues had a favorable and an unfavorable conformation for deamidation (Figure 3 and Supplementary Table 5). Considering the orientation of side chain and distance between C-N bond (electrophile-nucleophile distance), the conformation of HC Asn384 in PDB 1FC1 with a ψ angle of −122.7° and a Ψ-N distance of 2.8Å was more favorable for deamidation than the one in PDB 4W4O with a ψ angle of 38.0° and a Ψ-N distance of 5.0Å (Figure 3A). For a similar reason, the conformation of HC Asn389 in PDB 4W4O with a ψ angle of −18.3° and a Ψ-N distance of 3.5Å was more favorable for deamidation than the one in PDB 4BYH with a ψ angle of 9.6° and Ψ-N distance of 5.0Å (Figure 3B).

Two distinct peptide geometries for HC Asn 384 and HC Asn389 lead to four possible combinations: unfavorable deamidation conformations for both residues, favorable deamidation conformations for both residues, or combinations of unfavorable and favorable conformations for the pair. Unfavorable deamidation conformations were commonly observed for both residues in the
deposited Fc crystals grown in acidic or neutral pH conditions, which explained their slow deamidation rates observed under acidic or neutral pH conditions. In contrast, the rate constants for HC Asn384/Asn389 deamidation increased over 100-fold under basic pH conditions, which suggested that a conformational change induced by basic pH conditions might have increased the rate of backbone NH group deprotonation and facilitated formation of the cyclic succinimide intermediate. In summary, HC Asn384 and HC Asn389 in the Fc region appear to have at least two possible conformations with different deamidation rates, which likely contributed to the biphasic rates of deamidation observed at basic pH.

**Structural analysis of Asn325 deamidation**

In contrast to HC Asn384/389, HC Asn325 was more sensitive to deamidation in slightly acidic solutions. HC Asn325 is located at a β-turn structure within the FG loop of the CH2 domain. As shown in Figure 4A, HC Asn325 forms hydrogen bonds that help connect the FG loop with the BC loop. Thus, HC Asn325 is buried between the FG and BC loops with a low level of solvent accessible surface area (SASA). Since water plays a critical role in the deamidation reaction, possible correlations between HC Asn325 solvent accessibility and pH were investigated. Since IgG Fc structures reported in the PDB database were crystalized in buffers ranging from pH 4.0 to 7.0, the effect of pH on the local protein structure surrounding HC Asn325 could be evaluated by comparing the crystal structures obtained at the different pH values. To effectively compare the SASA of HC Asn325 in the different structural models, only IgG1 Fc crystal structures in the PDB with a resolution higher than 2.3 Å and clearly resolved backbone and sidechain structures in the 2Fo – Fc electron density maps were chosen for comparison.

---

**Figure 2.** Kinetic profiles for Asn deamidation under stressed conditions. The symbols are experimental data points and the lines represent the data fitting with exponential kinetic models described in the methods. K (observed deamidation constant) was obtained from the model fitting.
As shown in Table 1, there were no significant differences in distances between the Cγ of Asn325 and the backbone N atom of Lys326 in these Fc structural models. All distances were between 3.0 and 3.5 Å. However, there were large variations in the calculated SASA values for HC Asn325 in these structural models. As shown in Table 1 and Figure 4B, the SASA values for HC Asn325 showed a negative correlation against the buffer pH used in crystallization. These results suggested that pH affected the local 3D structure near HC Asn325, and were consistent with the observed increase in deamidation in heat stressed samples at acidic pH.

Comparison between the PDB 4BYH and PDB 2DTS structural models further illustrated the effect of pH on the local protein conformation around HC Asn325. The crystals used for the PDB 4BYH structure model were grown at pH 4.0 and the calculated SASA value for HC Asn325 was 14.0 Å². In contrast, the crystals used for the PDB 2DTS structure model were grown at pH 7.0 and the calculated SASA value for HC Asn325 in was only 3.9 Å², which was about 28% of the value obtained at pH 4.0. An overlay of these two structure models revealed major conformational changes in the BC loop, which may have led to the significant differences in the SASA values (Figure 4C,D). A comparison of these two structural models also suggested that HC His268 may help trigger the BC loop conformational change under different pH. Since the histidine sidechain imidazole ring has a pKa around 6.0, protonation of HC His268 in the 4BYH structural model at pH 4.0 may lead to the formation of a salt bridge with HC Glu294 (Figure 4C). In contrast, deprotonation of HC His268 at pH 7.0 could break the salt bridge in the 2DTS structural model and lead to the conformational changes in the BC loop and reduced solvent accessibility for Asn325. These results indicate that the solvent accessibility of HC Asn325 might be the major factor contributing to its low deamidation rate at neutral or basic pH.

Deamidation of Asn325 and Asn384/389 in IgG4 mAbs

IgG4 mAbs, which are one of four human IgG subclasses, share over 90% sequence identity with IgG1 mAbs in the constant region. Recent crystal structure studies of IgG4 mAbs had revealed significant conformational differences in the Fc regions between IgG1 and IgG4, which can explain their distinctive biological properties. The three most sensitive Asn residues in the IgG1 Fc region, Asn325 and Asn384 and Asn389, are conserved in IgG4 mAbs with the same sequence motifs (N-K, N-G and N-N for Asn325, Asn384 and Asn389, respectively). To understand how the conformational changes may impact the deamidation kinetics of these three Asn residues, we quantified Asn325 and Asn384/389 deamidation levels in five human IgG4 mAbs when incubated at 37°C up to 90 days in acidic formulation buffer (pH 5.0 – 5.8). The deamidation rate constants were then calculated by fitting the experimental peptide mapping data with the exponential first-order kinetics model.

As shown in Figure 5A, the measured deamidation rate constants of Asn325 in five IgG4 mAbs were 2–3 fold lower than the rate constants for the three IgG1 mAbs. In contrast, there were no significant differences between the Asn384/389 deamidation rate constants for IgG4 and IgG1 mAbs. The higher deamidation rates for Asn325 in IgG1 mAbs were consistent with results from a recent published study, which demonstrated that the overall changes in the BC loop and reduced solvent accessibility for Asn325. These results indicate that the solvent accessibility of HC Asn325 might be the major factor contributing to its low deamidation rate at neutral or basic pH.

Table 3. Structural analysis of Asn deamidation in the Fv region.

| Group | Antibodies | Residue Number | Sequence Motif | Secondary Structure | Cγ-N distance (Å) | SASAb (Å²) | Deamidation Under Normal Storage Conditions | Deamidation Under Stressed Conditions |
|-------|------------|----------------|---------------|---------------------|------------------|------------|---------------------------------|-----------------------------------|
| I     | mAb2       | LC Asn76       | SINTV         | β-sheet             | 3.9              | 52.3       | Low                             | Low                               |
|       | mAb2       | LC Asn103      | GTNLE         | β-sheet             | 3.2              | 30.5       | Low                             | Low                               |
|       | mAb2       | HC Asn35       | WMNNWV        | β-sheet             | 4.4              | 0          | Low                             | Low                               |
|       | mAb2       | HC Asn101      | SNNHY         | β-sheet             | 3.4              | 0          | Low                             | Low                               |
|       | mAb3       | LC Asn53       | ASNRA         | β-sheet             | 4.7              | 67.8       | Low                             | Low                               |
|       | mAb3       | HC Asn57       | GSNNK         | β-sheet             | 4.5              | 71.4       | Low                             | Low                               |
|       | mAb3       | HC Asn77       | SKNNTL        | β-sheet             | 5.0              | 53.3       | Low                             | Low                               |
|       | mAb3       | HC Asn84       | QMNSL         | β-sheet             | 4.5              | 31.1       | Low                             | Low                               |
|       | mAb1       | LC Asn53       | ASNRA         | β-sheet             | 4.8              | 65.5       | Low                             | Low                               |
|       | mAb1       | HC Asn77       | SKNNTL        | β-sheet             | 4.9              | 58.7       | Low                             | Low                               |
|       | mAb1       | HC Asn84       | QMNSL         | β-sheet             | 4.4              | 63.2       | Low                             | Low                               |
|       | mAb4       | LC Asn52       | MSNLA         | β-sheet             | 4.7              | 60.1       | Low                             | Low                               |
|       | mAb4       | HC Asn77       | ARNSL         | β-sheet             | 5.0              | 43.3       | Low                             | Low                               |
|       | mAb4       | HC Asn84       | QMNSL         | β-sheet             | 4.5              | 61.1       | Low                             | Low                               |
| II    | mAb2       | LC Asn41       | RTNGS         | β-turn              | 4.9              | 170.8      | Low                             | Low                               |
|       | mAb2       | HC Asn31       | FSNHW         | α-helix             | 4.6              | 10.9       | Low                             | Low                               |
|       | mAb3       | HC Asn74       | RDNSK         | loop                | 4.6              | 45.7       | Low                             | Low                               |
|       | mAb3       | HC Asn107      | GDNYY         | loop                | 4.9              | 26.8       | Low                             | Low                               |
|       | mAb5       | LC Asn53       | YGNKS         | β-turn              | 4.5              | 30.4       | Low                             | High                              |
|       | mAb5       | HC Asn31       | FSNYW         | α-helix             | 4.9              | 107.6      | Low                             | Low                               |
|       | mAb5       | HC Asn55       | PSNSY         | loop                | 3.8              | 107.6      | Low                             | High                              |
|       | mAb1       | LC Asn93       | RSNWP         | loop                | 3.6              | 62.2       | Low                             | Low                               |
|       | mAb1       | HC Asn107      | TFNSF         | α-helix             | 3.7              | 77.4       | Low                             | Low                               |
|       | mAb1       | HC Asn74       | RDNKS         | β-turn              | 4.7              | 44.9       | Low                             | Low                               |
|       | mAb4       | HC Asn74       | RDNAK         | loop                | 4.6              | 43.3       | Low                             | Low                               |
| III   | mAb3       | LC Asn93       | RSNWP         | loop                | 2.5              | 0.4        | Low                             | High                              |
|       | mAb5       | LC Asn28       | SSNSG         | β-sheet             | 3.1              | 0          | Low                             | High                              |
| IV    | mAb2       | HC Asn57       | SINGA         | β-turn              | 2.9c             | 124        | Low                             | High                              |
|       | mAb3       | HC Asn43       | PNGNL         | β-turn              | 2.8              | 100.5      | High                            | High                              |

a Cγ-N distance is the distance between Cγ of Asn residue and N of Asn C-terminal adjacent residue.
b SASA = Solvent Accessible Surface Area.
c calculation was based on the PDB 4GJ3 structure model.
Deamidation rates for IgG1 mAbs were faster than IgG4 mAbs with identical variable regions.

To understand the molecular basis for these different deamidation rates of Asn325 in IgG4, three IgG4 Fc crystal structure models available in the PDB database with a resolution higher than 2.4 Å were chosen for further structure analysis. Alignment of the IgG1 and IgG4 Fc structures revealed major conformational changes in the FG loop of the CH2 domain (Figure 5B). Compared to IgG1, the FG loop in IgG4 is further away from the BC loop, which increases the distances between Cγ of Asn325 and the backbone N atom of Lys326 from around 3.2 Å in IgG1 to 4.7 Å in IgG4 (Figure 5B and Table 1). This longer distance in IgG4 is predicted to decrease the chances for nucleophilic attack on the carbonyl carbon and would explain the slower rates of Asn325 deamidation observed in IgG4 mAbs.

Structural analysis of sensitive Asn deamidation sites in the Fv region

Deamidation of LC Asn28, LC Asn53, HC Asn55 and LC Asn93 in the Fv region was low under unstressed storage conditions, but increased significantly under high pH stress conditions. Structure analysis of those four sensitive sites revealed that the Asn residues were stabilized in unfavorable deamidation conformations by a few intra-molecular hydrogen bonds. In the cases of LC Asn53 and HC Asn55, the Cγ-N distances were >3.4 Å, which is longer than the proposed ideal conformation for deamidation. In the cases of LC-Asn28 and LC-Asn93, the Asn residues were buried and had low solvent accessibility. These analyses suggested that incubation of the mAbs under heat stress conditions at pH 8.5 might have induced conformational changes leading to a more favorable one for deamidation.

A decision tree for predicting Asn deamidation propensity

A decision tree was created to predict the deamidation propensity of Asn residues based on the observed experimental data and available structural models. There are more than 20 crystal structures of human IgG1 Fc regions in the PDB with almost identical back bone structures, except for a few differences in the flexible loop regions. One high resolution crystal
The structure of the IgG1 Fc region (PDB: 4W4O, resolution 1.8 Å) was chosen to calculate the structural parameters for all ten Asn residues in the Fc region. The PDB 4BYH and 1FC1 structures were used for the alternative conformations of HC Asn386 and HC Asn389. Crystal structures of mAb2 (PDB 4G3Y) and mAb5 and homology models of the mAb1, mAb3 and mAb4 Fab regions were used to calculate the structural parameters for the Asn residues in the Fv region. As shown in Figure 6, all Asn residues could be divided into four groups (Group I-IV) based on the observed deamidation rates and the three structural parameters: backbone flexibility, Cγ-N distance and solvent accessibility. These three structural parameters seemed to have a major impact on the observed deamidation rates and could be used to predict deamidation propensity of IgG1 mAbs. The propensity of Asn deamidation likely increases from group I to group...
IV due to increases in backbone flexibility, decreases in Cγ-N distance and increases in solvent accessibility.

The Group I Asn residues are low risk deamidation sites under both unstressed and stressed conditions because of their relatively rigid β-sheet conformations. β-sheets are the major secondary structure component in IgG mAbs. It is stabilized by multiple hydrogen bonds between adjacent β-strands and the peptide backbone has a dihedral angle (ψ) of 135° that is far from the ideal angle (ψ) of −120° needed to form the succinimide intermediate. Both factors lead to rigid peptide geometry and inhibits deamidation reaction. Consistent with this hypothesis, there were no increases in deamidation of the β-sheets Asn residues under stressed conditions (Tables 2 and 3), further indicating that these are the least favorable deamidation sites in IgG1 mAbs.

Group II Asn residues are also considered to be low risk because the Cγ-N distances were too long to form a stable succinimide intermediate. Based on the empirical data and structure analysis presented in Tables 2 and 3, Asn residues with Cγ-N distance > 3.4 Å had a low deamidation propensity. The only exceptions were LC Asn53 and HC Asn55 from mAb5, which are located at flexible loop structures with a NS sequence motif, which could deamidate under high pH stress conditions.

Group III Asn residues have a Cγ-N distance (< 3.4 Å) short enough to form the succinimide intermediate, and thus could deamidate under high pH stress conditions. However, they do not deamidate at acidic pH due to low solvent accessibility (SASA < 10 Å).2

Group IV Asn residues have Cγ-N distance < 3.4 Å and SASA values > 10 Å. These Asn residues are considered high risk deamidation sites under both unstressed and stressed conditions due to their ideal geometry for deamidation.

In most cases, the estimated deamidation risk derived from this decision tree matched very well to the experimental data. However, one exception is HC Asn57 from mAb2. Structure analysis suggested that this should be a high-risk residue in Group IV, but only 2% deamidation was detected in the unstressed mAb (Supplementary Table 2).

To understand this discrepancy, the deposited mAb2 crystal structure (PDB: 4G3Y23) was examined carefully. Ramachandran plot analysis, which is used to calculate peptide φ and ψ angles, revealed that the backbone geometry of HC Asn57 was outside of the theoretically allowed region, which indicated that the structure model around HC Asn57 may have been built incorrectly.10 As shown in Figure 7A, the backbone carbonyl of HC Asn57 in the original structure model did not match the calculated electron density map. The CDR-H2 loop structure model was refined by flipping the original HC Asn57 backbone carbonyl and then fitting the rest of the loop. The refined model appeared to match the electron density map much better and resulted in a peptide geometry that was within the allowed region. However, the moderate resolution (2.6 Å) of this crystal structure did not allow reliable modeling of this flexible loop. Therefore, Molecular Dynamic (MD) simulations were used to assess which of these two conformations was more stable.

The stability of the HC Asn57 conformation was assessed by generating MD trajectories. The MD trajectories were initiated using two Fv structure models that were identical except for the conformation of the CDR-H2 loop. In the first trajectory, the conformation of CDR-H2 in the initial model was taken from the published crystal structure (4G3Y), whereas, in the second trajectory, the structure of CDR-H2 loop was taken from the refined model based on the deposited electron density map. For both starting models, trajectories lasting 5 ns were generated. As shown in Figure 7B, the trajectory with the refined HC Asn57 conformation was more stable over the length of simulation. The ψ angle of HC Asn57 oscillated around 42° for the trajectory with the refined HC Asn57 conformation. In contrast, the trajectory with the original HC Asn57 conformation was unstable. At the beginning of the simulation, the backbone carbonyl of HC Asn57 oscillated around −100°. Before the simulation time reached 2ns, the backbone carbonyl flipped positions and oscillated around 42°, which was within the same range as the refined structure model. In conclusion, the MD simulation results indicated that the refined HC Asn57 conformation model was more energetically favorable than the original model.

The HC Asn57 deamidation risk was then re-evaluated using the refined mAb2 structure. Following the decision tree, HC Asn57 was re-assigned to Group II because the Cγ-N distance and increases in solvent accessibility.

**Figure 6.** Decision tree for predicting Asn deamidation hot spots. Three structure parameters, β-sheet structure, Cγ-N distance and SASA were used to assign Asn residues into 4 groups with increased deamidation propensities.
Figure 7. Structural models for HC Asn57. The conformation of HC Asn57 from original crystal structure model (PDB: 4G3Y) is not energetically favorable. A) Structure overlays of CDR-H2 loops between the original crystal structure model and refined model. The electron density map (2Fo-Fc) was shown as grey mesh at a contour level of 1σ. B) Upper panel, overlays of instantaneous structures of CDR-H2 loops at 5 ns from molecular dynamic trajectories obtained. (Left) original model (Right) refined model. Lower panel, psi angels for Asn57 during the MD simulations for both original and refined structure models.
N distance increased from 2.9 Å in the original model to 4.4 Å in the refined structure model, which was outside the optimal range (3.4 Å). However, the deamidation risk for HC Asn57 is predicted to be high under stressed conditions because HC Asn57 is in a flexible loop region with NS sequence motif. Both predictions matched the experimental results (Figure 2 and Supplementary Table 2). Taken together, the predicted deamidation propensities obtained from the decision tree for all Asn residues were consistent with the experimental results.

Discussion

Although the mechanism of deamidation has been well studied, a reliable method to predict Asn deamidation “hot spots” for IgG mAbs remains a challenge. As described here, correlations between the experimental deamidation results for IgG1 and IgG4 mAbs and three-dimensional protein structures indicated that the observed differences in Asn deamidation rates could be attributed to differences in the backbone flexibility, Cγ-N distance and solvent accessibility. This information was further utilized to establish a structure-based decision tree that can more accurately predict the Asn deamidation risk than using amino acid sequence motif alone. The decision tree can be utilized to predict the in vitro and in vivo stability of mAbs, or design molecules with increase stability. Although this structure-based decision tree was derived from IgG1 mAb analysis, the same principles are likely applicable to non-mAb protein therapeutics as well.

The structural analysis also helped to explain the unique deamination behavior of HC Asn325 in IgG1 mAbs. In contrast to other Asn residues, HC Asn325 was more susceptible to deamidation in acidic buffers, but remained stable at basic or neutral pH. Structural analysis indicated that deprotonation of the adjacent HC His268 at pH 7.0 and above would break the salt bridge between HC His268 and HC Glu294, which would trigger a change in the BC loop conformation and significantly reduce the solvent accessibility of HC Asn325. Comparison of IgG1 and IgG4 Fc structure models also reveals that conformational changes at the CH2 domain result in the longer Asn325 Cγ-N distance in IgG4 than that in IgG1, which would explain the slower rates of Asn325 deamidation in IgG4 mAbs.

Analysis of structural models also indicated that HC Asn389 and HC Asn394 had two distinct conformations for deamidation, with unfavorable conformations dominant under neutral or acidic conditions. This observation explained the low deamidation rates for these two residues under neutral or acidic conditions, and the biphasic deamidation curves observed in basic solutions.

Materials and methods

Preparation of stressed mAbs

Unstressed mAb samples were stored in the formulation buffer, pH 5.0 ~ 5.8, at −70°C. For the heat stress studies, samples were incubated at 37°C for up to 180 days. For the high pH stress studies, samples were dialyzed to pH 8.5 phosphate buffer and incubated at 37°C for up to 30 days. Stressed samples were aliquoted out at individual time points and dialyzed back to their original formulation buffer and store at −70°C prior to analysis.

Lys-C peptide mapping

0.2 mg mAb sample was denatured with 150 µL of 6 M guanidine hydrochloride, 50 mM Tris-HCl, 5 mM ethylenediaminetetraacetic acid, pH 8.0. Denatured protein was reduced with 1.5 µL of 1.0 M dithiothreitol (DTT) at 37°C for 1 hour and alkylated with 3.0 µL of 1 M sodium iodoacetamide at room temperature in the darkness for 1 hour. The reaction was quenched by adding 1.0 µL of 1.0 M DTT. The reduced and alkylated sample was then diluted with 750 µL of 50 mM Tris-HCl, pH 8.0 and digested with Lys-C at an enzyme/protein ratio of 1:25 (w/w) for 4 hours at 37°C. The reaction was quenched by adding 5 µL of trifluoroacetic acid (TFA), and the resultant peptides were separated by reverse-phase HPLC using a narrow bore C18 column (Vydac, 218TP5215, 2.1 mm x 150 mm) and a gradient of acetonitrile/water/0.1% TFA. LC/MS/MS analysis was performed using an Agilent 1100 HPLC coupled on-line with Orbitrap XL mass spectrometer (Thermo Electron) with an electrospray source. Deamidated was quantified by extracted ion current chromatograms, and percentage deamidation was expressed as the levels of modified peptides as percentages of total peptide peak areas (native + modified peptides).

Deamidation kinetics analysis

Observed deamidation rates followed exponential first-order kinetics as described previously. The observed first-order rate constants (K) were calculated by nonlinear least-squares regression analysis using the software Graphpad Prizm. The following equation was used for the fitting:

\[ A = A_0 + (A_\infty - A_0) \times [1 - e^{-Kt}] \]

where A was the percentage of Asn deamidation at time t, A0 was the initial percentage of Asn deamidation at Time 0, A\_\infty was the maximal percentage of Asn deamidation. A\_\infty was set at 100 for all Asn residues except Asn384/389, which was set at 60.

Structure homology modeling

The homology structure models for the Fv region were generated and optimized by Discovery Studio, version 4.0 (Accelrys Software) “Model antibody”. The templates used for structure modeling were chosen based on sequence alignments. Templates for light, heavy and light-heavy interface framework were chosen independently.

Molecular dynamics simulation

The molecular dynamic simulations were performed with Discovery Studio, version 4.0. The starting structure for mAb2 was taken from Protein Data Bank (PDB) entry 4G3Y, with all solvent molecules removed. Based on
the deposited electron density maps, a refined model was built by flipping the original Asn57 backbone conformation. Hydrogen atoms were added to the models automatically, using Discovery Studio tool. All simulations were performed in 0.15 M NaCl and with a zero net charge of the system. For the imposition of periodic boundary conditions, protein models were centered in a rhombic dodecahedral box with a minimum distance to the edge of 10 Å. System energies were minimized using the steepest descent method. Equilibration was then conducted in two steps, with positional restraints applied to all non-hydrogen protein atoms. Unrestrained production trajectories were then generated for 5 ns, using the same NPT ensemble conditions. Three replicates of each simulation were generated using different sets of random initial velocities to start the NVT equilibration step of each replicate. Coordinates and energies were saved every 10 ps for analysis.

**Abbreviations**

| Abbreviation | Definition |
|--------------|------------|
| Asn          | Asparagine |
| Asp          | Aspartate  |
| CDR          | Complementary-determining regions |
| DTT          | Dithiothreitol |
| Fv           | Fragment variable |
| HC           | Heavy chain |
| isoAsp       | Isoaspartate |
| LC/MS        | Liquid chromatography/mass spectrometry |
| LC           | Light chain |
| mAbs         | Monoclonal antibodies |
| MD           | Molecular Dynamic |
| PDB          | Protein DataBank |
| PK           | Pharmacokinetics |
| SASA         | Solvent accessible surface area |
| TFA          | Trifluoroacetic acid |

**Acknowledgments**

We would like to thank Dr. Mehul Patel for his continuing support of exploring novel technologies for biopharmaceutical development, Dr. Jinquan Luo and Dr. Gary Gilliland for their support on the structural analysis, and Dr. Michael Nedved for many helpful discussions.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was supported by the Janssen Research and Development;

**ORCID**

Qingrong Yan [http://orcid.org/0000-0001-9434-1540](http://orcid.org/0000-0001-9434-1540)

**References**

1. Haberger M, Romans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes. Mabs. 2014;6:327–339. doi:10.4161/mabs.27876.

2. Huang L, Lu J, Wroblewski VJ, Beals JM, Riggan RM. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem. 2005;77:1432–1439. doi:10.1021/ac0494174.

3. Yan B, Steen S, Hambr D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci. 2009;98:3509–3521. doi:10.1002/jps.21655.

4. Harris RJ, Kabakoff B, Macchi FD, Shen F, Kwong M, Andya JD, Shire SJ, Bjork N, Topal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 2001;723:233–245.

5. Bumbaca Yadav D, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, et al. Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics. J Biol Chem. 2015;290:29732–29741. doi:10.1074/jbc.M115.692434.

6. Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci USA. 2015;112:5997–6002. doi:10.1073/pnas.1408766112.

7. Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 262;1987:785–794.

8. Stephenson RC, Clarke S. Succinimide formation from asparaginyl and aspartaginyl peptides as a model for the spontaneous degradation of proteins. J Biol Chem. 264;1989:6164–6170.

9. Xie M, Schowen RL. Secondary structure and protein deamidation. J Pharm Sci. 1999;88:8–13. doi:10.1021/jp9802493.

10. Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharm Res. 2007;24:1145–1156. doi:10.1007/s11095-007-9241-4.

11. Robinson NE, Robinson AB. Prediction of primary structure deamidation rates of asparaginyl and glutaminyl peptides through steric and catalytic effects. J Pept Res. 2004;63:437–448. doi:10.1111/j.1399-3011.2004.00148.x.

12. Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci USA. 2001;98:944–949. doi:10.1073/pnas.98.3.944.

13. Xie M, Shahrorkh Z, Kadkhodayan M, Hienzl WJ, Powell MF, Borchardt RT, Schowen RL. Asparagine deamidation in recombinant human lymphotixin: hindrance by three-dimensional structures. J Pharm Sci. 2003;92:869–880. doi:10.1021/jp0210342.

14. Kosky AA, Razzaq UO, Treuthel MJ, Brems DN. The effects of alpha-helix on the stability of Asn residues: deamidation rates in peptides of varying helicity. Protein Sci. 1999;8:2519–2523. doi:10.1110/ps.8.11.2519.

15. Robinson NE, Robinson AB. Prediction of protein deamidation rates from primary and three-dimensional structure. Proc Natl Acad Sci USA. 2001;98:4367–4372. doi:10.1073/pnas.010666498.

16. Sydow JF, Lipsmeier F, Larralet V, Hilger M, Mautz B, Molhoj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, et al. Structure-based prediction of asparagine and aspartate degradations sites in antibody variable regions. PLoS One. 2014;9:e100736. doi:10.1371/journal.pone.0100736.

17. Capasso S. Estimation of the deamidation rate of asparagine side chains. J Pept Res. 2005;60:224–229.

18. Peters B, Trout BL. Asparagine deamidation: pH-dependent mechanism from density functional theory. Biochemistry. 2006;45:5384–5392. doi:10.1021/bi052438n.

19. Chelius D, Rehder DS, Bondarenko PV. Identification and characterization of deamidation sites in the conserved regions of
human immunoglobulin gamma antibodies. Anal Chem. 2005;77:6004–6011. doi:10.1021/ac050672d.

20. Zhang YT, Hu J, Pace AL, Wong R, Wang YJ, Kao YH. Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;965:65–71. doi:10.1016/j.jchromb.2014.06.018.

21. Davies AM, Sutton BJ. Human IgG4: a structural perspective. Immunol Rev. 2015;268:139–159. doi:10.1111/imr.12349.

22. Neergaard MS, Nielsen AD, Parshad H, Van De Weert M. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass. J Pharm Sci. 2014;103:115–127. doi:10.1002/jps.23788.

23. Liang S, Dai J, Hou S, Su L, Zhang D, Guo H, Hu S, Wang H, Rao Z, Guo Y, et al. Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab. J Biol Chem. 2013;288:13799–13807. doi:10.1074/jbc.M112.433961.